Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

被引：206

作者：

Yamazaki, K. ^{[1
]}

Nagase, M. ^{[2
]}

Tamagawa, H. ^{[3
]}

Ueda, S. ^{[4
]}

Tamura, T. ^{[5
]}

Murata, K. ^{[6
]}

Nakajima, T. Eguchi ^{[7
]}

Baba, E. ^{[8
]}

Tsuda, M. ^{[9
]}

Moriwaki, T. ^{[10
]}

Esaki, T. ^{[11
]}

Tsuji, Y. ^{[12
]}

Muro, K. ^{[13
]}

Taira, K. ^{[14
]}

Denda, T. ^{[15
]}

Funai, S. ^{[16
]}

Shinozaki, K. ^{[17
]}

Yamashita, H. ^{[18
]}

Sugimoto, N. ^{[19
]}

Okuno, T. ^{[20
]}

Nishina, T. ^{[21
]}

Umeki, M. ^{[22
]}

Kurimoto, T. ^{[23
]}

Takayama, T. ^{[24
]}

Tsuji, A. ^{[25
]}

Yoshida, M. ^{[26
]}

Hosokawa, A. ^{[27
]}

Shibata, Y. ^{[28
]}

Suyama, K. ^{[29
]}

Okabe, M. ^{[30
]}

Suzuki, K. ^{[31
]}

Seki, N. ^{[32
]}

Kawakami, K. ^{[33
]}

Sato, M. ^{[34
]}

Fujikawa, K. ^{[35
]}

Hirashima, T. ^{[36
]}

Shimura, T. ^{[37
]}

Taku, K. ^{[38
]}

Otsuji, T. ^{[39
]}

Tamura, F. ^{[40
]}

Shinozaki, E. ^{[41
]}

Nakashima, K. ^{[42
]}

Hara, H. ^{[43
]}

Tsushima, T. ^{[1
]}

Ando, M. ^{[44
]}

Morita, S. ^{[45
]}

Boku, N. ^{[7
]}

Hyodo, I. ^{[10
]}

机构：

[1] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, 1007 Shimonagakubo, Nagaizumi, Shizuoka 4118777, Japan

[2] Jichi Med Univ, Dept Clin Oncol, Shimotsuke, Japan

[3] Osaka Gen Med Ctr, Dept Surg, Osaka, Japan

[4] Kinki Univ, Dept Med Oncol, Fac Med, Higashiosaka, Osaka, Japan

[5] Kinki Univ, Dept Med Oncol, Nara Hosp, Fac Med, Ikoma, Japan

[6] Suita Municipal Hosp, Dept Surg, Suita, Osaka, Japan

[7] St Marianna Univ, Dept Clin Oncol, Sch Med, Kawasaki, Kanagawa, Japan

[8] Kyushu Univ, Dept Comprehens Clin Oncol, Fac Med Sci, Fukuoka, Japan

[9] Hyogo Canc Ctr, Dept Gastroenterol Oncol, Akashi, Hyogo, Japan

[10] Univ Tsukuba, Div Gastroenterol, Tsukuba, Ibaraki, Japan

[11] Natl Hosp Org Kyushu Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan

[12] Tonan Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[13] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[14] Osaka City Gen Hosp, Clin Oncol, Osaka, Japan

[15] Chiba Canc Ctr, Div Gastroenterol, Chiba, Japan

[16] Kinki Univ, Dept Surg, Sakai Hosp, Fac Med, Sakai, Osaka, Japan

[17] Hiroshima Prefectural Hosp, Div Clin Oncol, Hiroshima, Japan

[18] Okayama Med Ctr, Dept Gastroenterol & Hepatol, Okayama, Japan

[19] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Clin Oncol, Osaka, Japan

[20] Kobe Univ, Dept Internal Med, Div Gastroenterol, Grad Sch Med, Kobe, Hyogo, Japan

[21] Natl Hosp Org Shikoku Canc Ctr, Dept Gastrointestinal Med Oncol, Matsuyama, Japan

[22] Hyogo Prefectural Awaji Med Ctr, Dept Surg, Sumoto, Japan

[23] Nagoya Kyoritsu Hosp, Dept Gastrointestinal Oncol, Nagoya, Aichi, Japan

[24] Univ Tokushima, Dept Gastroenterol & Oncol, Grad Sch, Tokushima, Japan

[25] Kochi Hlth Sci Ctr, Dept Med Oncol, Kochi, Japan

[26] Osaka Med Coll Hosp, Div Canc Chemotherapy Ctr, Takatsuki, Osaka, Japan

[27] Toyama Univ, Dept Gastroenterol & Hematol, Fac Med, Toyama, Japan

[28] Miyazaki Prefectural Miyazaki Hosp, Dept Chemotherapy, Miyazaki, Japan

[29] Toranomon Gen Hosp, Dept Med Oncol, Tokyo, Japan

[30] Kurashiki Cent Hosp, Dept Surg, Kurashiki, Okayama, Japan

[31] Kushiro City Gen Hosp, Dept Gastroenterol, Kushiro, Hokkaido, Japan

[32] Teikyo Univ, Dept Internal Med, Div Med Oncol, Sch Med, Tokyo, Japan

[33] Muroran City Gen Hosp, Dept Gastroenterol, Muroran, Hokkaido, Japan

[34] Ryuugasaki Saiseikai Hosp, Dept Gastroenterol & Hepatol, Ryugasaki, Japan

[35] Hokkaido Canc Ctr, Dept Gastroenterol, Sapporo, Hokkaido, Japan

[36] Osaka Prefectural Med Ctr Resp & Allerg Dis, Dept Thorac Malignancy, Habikino, Japan

[37] Nagoya City Univ, Dept Gastroenterol & Metab, Grad Sch Med Sci, Nagoya, Aichi, Japan

[38] Shizuoka Prefectural Gen Hosp, Div Med Oncol, Shizuoka, Japan

[39] Dongo Hosp, Dept Gastroenterol, Yamatotakada, Japan

[40] Kumamoto Reg Med Ctr, Dept Gastroenterol, Kumamoto, Japan

[41] Canc Inst Hosp JFCR, Dept Gastroenterol, Tokyo, Japan

[42] Miyazaki Univ, Dept Internal Med 1, Fac Med, Miyazaki, Japan

[43] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan

[44] Nagoya Univ Hosp, Ctr Adv Med & Clin Res, Nagoya, Aichi, Japan

[45] Kyoto Univ, Dept Biomed Stat & Bioinformat, Grad Sch Med, Kyoto, Japan

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷 / 08期

关键词：

irinotecan; oxaliplatin; bevacizumab; colorectal cancer; phase III study; CONTROLLED-TRIAL; OPEN-LABEL; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; IRINOTECAN; CHEMOTHERAPY; COMBINATION; CETUXIMAB; THERAPY;

D O I：

10.1093/annonc/mdw206

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This randomized phase III trial compared FOLFIRI plus bevacizumab with mFOLFOX6 plus bevacizumab as the first-line treatment for patients with metastatic colorectal cancer. This direct comparative phase III trial demonstrated that FOLFIRI plus bevacizumab was non-inferior to mFOLFOX6 plus bevacizumab in terms of progression-free survival, and was associated with favorable quality of life profiles.FOLFIRI and FOLFOX have shown equivalent efficacy for metastatic colorectal cancer (mCRC), but their comparative effectiveness is unknown when combined with bevacizumab. WJOG4407G was a randomized, open-label, phase III trial conducted in Japan. Patients with previously untreated mCRC were randomized 1:1 to receive either FOLFIRI plus bevacizumab (FOLFIRI + Bev) or mFOLFOX6 plus bevacizumab (mFOLFOX6 + Bev), stratified by institution, adjuvant chemotherapy, and liver-limited disease. The primary end point was non-inferiority of FOLFIRI + Bev to mFOLFOX6 + Bev in progression-free survival (PFS), with an expected hazard ratio (HR) of 0.9 and non-inferiority margin of 1.25 (power 0.85, one-sided alpha-error 0.025). The secondary end points were response rate (RR), overall survival (OS), safety, and quality of life (QoL) during 18 months. This trial is registered to the University Hospital Medical Information Network, number UMIN000001396. Among 402 patients enrolled from September 2008 to January 2012, 395 patients were eligible for efficacy analysis. The median PFS for FOLFIRI + Bev (n = 197) and mFOLFOX6 + Bev (n = 198) were 12.1 and 10.7 months, respectively [HR, 0.905; 95% confidence interval (CI) 0.723-1.133; P = 0.003 for non-inferiority]. The median OS for FOLFIRI + Bev and mFOLFOX6 + Bev were 31.4 and 30.1 months, respectively (HR, 0.990; 95% CI 0.785-1.249). The best overall RRs were 64% for FOLFIRI + Bev and 62% for mFOLFOX6 + Bev. The common grade 3 or higher adverse events were leukopenia (11% in FOLFIRI + Bev/5% in mFOLFOX6 + Bev), neutropenia (46%/35%), diarrhea (9%/5%), febrile neutropenia (5%/2%), peripheral neuropathy (0%/22%), and venous thromboembolism (6%/2%). The QoL assessed by FACT-C (TOI-PFC) and FACT/GOG-Ntx was favorable for FOLFIRI + Bev during 18 months. FOLFIRI plus bevacizumab was non-inferior for PFS, compared with mFOLFOX6 plus bevacizumab, as the first-line systemic treatment for mCRC. UMIN000001396.

引用

页码：1539 / 1546

页数：8

共 18 条

[11] Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Loupakis, Fotios
Cremolini, Chiara
Masi, Gianluca
Lonardi, Sara
Zagonel, Vittorina
Salvatore, Lisa
Cortesi, Enrico
Tomasello, Gianluca
Ronzoni, Monica
Spadi, Rosella
Zaniboni, Alberto
Tonini, Giuseppe
Buonadonna, Angela
Amoroso, Domenico
Chiara, Silvana
Carlomagno, Chiara
Boni, Corrado
Allegrini, Giacomo
Boni, Luca
Falcone, Alfredo
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (17) : 1609 - 1618
[12] Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
Muro, Kei
Boku, Narikazu
Shimada, Yasuhiro
Tsuji, Akihito
Sameshima, Shinichi
Baba, Hideo
Satoh, Taroh
Denda, Tadamichi
Ina, Kenji
Nishina, Tomohiro
Yamaguchi, Kensei
Takiuchi, Hiroya
Esaki, Taito
Tokunaga, Shinya
Kuwano, Hiroyuki
Komatsu, Yoshito
Watanabe, Masahiko
Hyodo, Ichinosuke
Morita, Satoshi
Sugihara, Kenichi
[J]. LANCET ONCOLOGY, 2010, 11 (09) : 853 - 860
[13] Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Saltz, Leonard B.
Clarke, Stephen
Diaz-Rubio, Eduardo
Scheithauer, Werner
Figer, Arie
Wong, Ralph
Koski, Sheryl
Lichinitser, Mikhail
Yang, Tsai-Shen
Rivera, Fernando
Couture, Felix
Sirzen, Florin
Cassidy, Jim
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 2013 - 2019
[14] Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer
Sobrero, Alberto
Ackland, Stephen
Clarke, Stephen
Perez-Carrion, Ramon
Chiara, Silvia
Gapski, John
Mainwaring, Paul
Langer, Bernd
Young, Scott
[J]. ONCOLOGY, 2009, 77 (02) : 113 - 119
[15] Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Tol, Jolien
Koopman, Miriam
Cats, Annemieke
Rodenburg, Cees J.
Creemers, Geert J. M.
Schrama, Jolanda G.
Erdkamp, Frans L. G.
Vos, Allert H.
van Groeningen, Cees J.
Sinnige, Harm A. M.
Richel, Dirk J.
Voest, Emile E.
Dijkstra, Jeroen R.
Vink-Borger, Marianne E.
Antonini, Ninja F.
Mol, Linda
van Krieken, Johan H. J. M.
Dalesio, Otilia
Punt, Cornelis J. A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (06) : 563 - 572
[16] FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
Tournigand, C
André, T
Achille, E
Lledo, G
Flesh, M
Mery-Mignard, D
Quinaux, E
Couteau, C
Buyse, M
Ganem, G
Landi, B
Colin, P
Louvet, C
de Gramont, A
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) : 229 - 237
[17] Venook AP, 2014, J CLIN ONCOL, V32, P3
[18] Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial
Yamada, Yasuhide
Takahari, Daisuke
Matsumoto, Hiroshi
Baba, Hideo
Nakamura, Masato
Yoshida, Kazuhiro
Yoshida, Motoki
Iwamoto, Shigeyoshi
Shimada, Ken
Komatsu, Yoshito
Sasaki, Yasutsuna
Satoh, Taroh
Takahashi, Keiichi
Mishima, Hideyuki
Muro, Kei
Watanabe, Masahiko
Sakata, Yuh
Morita, Satoshi
Shimada, Yasuhiro
Sugihara, Kenichi
[J]. LANCET ONCOLOGY, 2013, 14 (13) : 1278 - 1286

← 1 2 →